(688139)"Qingdao Haier Biomedical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688139 · · 15 pages · Chinese
Summary by 6ix AI
The report highlights a notable increase in revenue and net profit compared to the previous year, driven by growth in both domestic and international markets. The company also emphasizes improvements in cash flow management and profitability metrics, despite some macroeconomic challenges.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Qingdao Haier Biomedical Co., Ltd. on 6ix
Earlier from Qingdao Haier Biomedical
- (688139)"Qingdao Haier Biomedical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688139)"Qingdao Haier Biomedical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- Haier Biomedical นำเสนอโซลูชันระบบจัดเก็บตัวอย่างชีวภาพอัตโนมัติและระบบเภสัชกรรมแบบเชื่อมต่ออัจฉริยะที่งาน ISPE Singapore 2026
- Haier Biomedical Tampilkan Biostoran Automatik dan Penyelesaian Farmaseutikal Terhubung di ISPE Singapore 2026
- Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Follow Qingdao Haier Biomedical into a list and get an email when it puts out news.
Follow Qingdao Haier Biomedical